XNAS
XTL Biopharmaceuticals Ltd is an intellectual property-based company focused on the development, management, and commercialization of intellectual property. The Company is engaged in biotechnology through its subsidiary Psyga Bio and in the biopharmaceutical industry with hCDR1, a novel compound working via a novel mechanism of action for the treatment of Systemic Lupus Erythematosus (SLE) and a potential treatment for Sjogren's syndrome (SS). It focuses on the acquisition and development of proprietary products and late-stage pharmaceutical product candidates for the treatment of unmet clinical needs.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | FY 2025 | — | -0.00 | — | $0 | — | +0.11% | +9.16% | — |
| 2024-12-30 | Q2 2024 | — | -0.00 | — | $0 | — | +8.91% | +8.69% | -12.90% |
| 2024-05-20 | Q1 2024 |
| — |
| 0.00 |
| — |
| $0 |
| — |
| +7.69% |
| +0.38% |
| -11.92% |
Showing last 3 quarters.